Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dulaglutide Depot
- Development stage
- Preclinical
- Lead developer
- Mapi Pharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
Dulaglutide Depot is an extended-release formulation of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Mapi Pharma using its proprietary long-acting depot technology. It is intended for the treatment of diabetes, specifically designed to provide a sustained release of the medication to improve patient compliance and therapeutic outcomes. As a GLP-1 receptor agonist, it enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and slows gastric emptying. The product is being developed via the 505(b)(2) regulatory pathway, referencing the approved drug Trulicity.
- Other names
- Dulaglutide Depot
02
Targets
Beyond the preview
Go deeper on Dulaglutide Depot.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dulaglutide Depot.